95 who died of UC. Five-year CSS was significantly worse for patients who underwent RC after PC versus primary RC (58% vs 67%; p¼0.02; HR 1.8; 95% CI 1.1, 3.0), while no significant difference in 5-year OS was noted (51% vs 54%; p¼0.42; HR 1.2; 95% CI 0.8, 1.7).
INTRODUCTION AND OBJECTIVES:
The impact of smoking on mortality in patients with bladder cancer is subject to controversies. METHODS: We investigated 1000 patients who consecutively underwent radical cystectomy between 1993 and 2013. Proportional hazard models for competing risks were used to study combined effects of variables on bladder cancer and competing mortality.
RESULTS: The median follow-up in the survivors was 6.6 years; 331 patients had died from bladder cancer, 178 from non-cancer or unknown (n¼6) causes and 54 from a second cancer. Compared with non-smokers, current smokers were more frequently male (35.7% versus 12.0%, p<0.0001), younger (63.5 versus 70.5 years, p<0.0001), had a lower body mass index (26.2 versus 27.1 kg/m2, p<0.0001) and suffered less frequently from cardiac insufficiency (12.7% versus 19.3%, p¼0.0129). In current smokers there was a trend towards lower bladder cancer and higher competing mortality compared with nonsmokers. In the multivariable analysis, current smoking was no predictor of bladder cancer mortality (hazard ratio, HR, in the full model 0.76, p¼0.0687) but of competing mortality (HR in the optimal model 1.62, p¼0.0044).
CONCLUSIONS: This study did not confirm adverse bladder cancer-related outcome in current smokers after radical cystectomy. With a younger mean age and a male predominance, current smokers showed a trend towards lower bladder cancer mortality that was eventually neutralized by increased competing mortality illustrating that selection effects may explain some smoking-related outcome differences after radical cystectomy. ASA score, TNM-classification and type of urinary diversion. We recorded the presence of urologic devices before RC, neo-adjuvant chemotherapy, previous radiotherapy, prolonged steroids therapy before RC, microbiological urine and blood cultures. UTI was diagnosed according to EAU/ESIU definitions. Primary objective was to analyze the type and length of antibiotic therapy (AB), the percentage and severity of UTIs after RC, the responsible bacteria and their AB sensitivity. We recorded the frequency of CT-scans and invasive procedures after RC and 30-days-readmission rate.
RESULTS: We analyzed 217 cases of RC. Median length of hospital stay was 13 days (IQR 11-20.5) with 9.2% of the patients still in hospital after 30 days. 30-days-readmission rate was 16.1%. The most frequent AB was a combination of metronidazole (98.2%) with a cephalosporin (89.9%). The median of days of AB administration after RC was 7 days . After cessation of the first AB therapy, additional antibiotics were used in 51.6% of the patients. The overall number of UTIs was 42 (19.4%): 9.7% pyelonephritis, 7.8% urosepsis, 1.8% uroseptic shock. Enterococcus spp. was the most frequently isolated bacteria in urine (25.7%) and in blood (42.9%). Enterococcus showed, as awaited, a cephalosporin (100%) and gentamicine (90%) resistance but also a 100% resistance to ciprofloxacin. In univariate logistic regression analysis, age (odds ratio (OR)¼0.94; p¼0.001), continent derivation (OR¼4.36; p<0.001), neoadjuvant chemotherapy (OR¼3.07; p¼0.044) and the presence of any urologic device before surgery (OR¼0.36; p¼0.013) were correlated with UTI. In multivariate logistic regression analysis only continent derivation was associated to UTI after surgery (OR¼3.16; p¼0.010).
CONCLUSIONS: The UTI rate after RC was 19.4% and in 9.6% of the cases UTI was urosepsis. Continent diversion was the only independent factor associated with a higher risk of UTI but perioperative AB therapy length was not. Enterococci spp. are involved in early infection and not routinely covered by the most common used AB prophylaxes.
Source of Funding: none

MP21-09 PROLONGED LENGTH OF STAY NOT ASSOCIATED WITH DECREASED HOSPITAL READMISSIONS FOLLOWING UNCOMPLICATED HOSPITALIZATION AFTER RADICAL CYSTECTOMY
Kirven Gilbert, Adam Lorentz*, Dattatraya Patil, Mehrdad Alemozaffar, Christopher Filson, Atlanta, GA INTRODUCTION AND OBJECTIVES: Clinical decision making regarding timing of discharge can vary widely for patients treated with radical cystectomy. Some patients may be kept in-house longer to diminish perceived risk of missed complications and subsequent readmission. We sought to evaluate the relationship between length of stay (LOS) and 30-day readmissions in patients who underwent radical cystectomy and did not experience in-hospital complications.
METHODS: We used data from the American College of Surgeons National Surgical Quality Improvement Program to identify bladder cancer patients who underwent radical cystectomy (2011) (2012) (2013) (2014) , and excluded patients who experienced in-hospital complications. Our primary outcome of interest was 30-day readmission, and main exposure was LOS in days (<6, 6-10, >10 days). Other factors of interest included race, gender, major complications after discharge, body mass index, and operative time (stratified by quartiles). Multivariable logistic regression was performed to estimate adjusted odds ratios for 30-day readmission.
RESULTS: Among 3,325 radical cystectomy patients who had an uncomplicated hospital stay, 718 (21.6%) were readmitted within 30 days after surgery. The median initial LOS was 7.0 days (interquartile range 6.0-9.0 days). A majority were discharged either between 6-10 days (42.1%) or >10 days after surgery (21.3%). Readmission was more common among patients who had post-discharge complications (35.1% vs 11.9% no complications, p<0.001) and increased operative time (29.7% top quartile vs 15.9% lowest quartile, p<0.001). Though readmitted patients had a shorter initial LOS on average (mean 7.8AE3.0 e250 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 
